Background: Alteration of radiation therapy (RT) fractionation and the combination of chemotherapy (CT) with RT represent two predominant fields of current research in the treatment ofhead and neck carcinomas. To assess the potential integration of these two fields, a retrospective comparison of toxicity and treatment outcome was carried out in stage III-IV patients treated with a concomitant boost RT schedule with or without CT.
Introduction
The prognosis of patients with advanced head and neck carcinomas treated by standard radiation therapy (RT) is generally very unfavorable [1] [2] [3] . Both the use of unconventional fractionation schedules and the adjunction of chemotherapy to RT are undergoing investigation in the hope of improving the se unsatisfactory results [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The encouraging initial results of the concomitant boost technique [9, 18] 1ed in 1991 to the introduction at the. University Hospital of Geneva of a modified concomitant boost schedule in which the boost to the clinically involved sites was delivered in a progressively accelerated fashion during the last 3.5 weeks of a 5.5 week treatment course. For stage III-IV disease, chemotherapy was initially added sequentially prior to RT and then progressively more frequently in a concomitant fashion. ln order to establish whether or not a concomitant boost schedule is compatible with the simultaneous administration of chemotherapy, the therapeutic outcome and toxicity of the combined treatment have been retrospectively analyzed and compared with those up for the surviving patients was 21 and 31 months for the RT and RT -CT groups respectively.
Results: Grade 3-4 acute toxicity (RTOG) was observed in 73% and 86% of patients, and grade 3 dysphagia in 31% and 57% (P =0.02) respectively in the RT and RT -CT groups. The rates of grade 3-4 late complications were simi1ar in the two groups (5% ys. 12%). At three years, actuaria1 loco-regional control (LRC) was 57% and 66% (P =0.66) and ove rail survival was 56% and 47% (P = 0.99) in the RT and RT -CT groups respectively.
Conclusions: White acute toxicity was higher compared with RT alone, this accelerated RT schedule was feasible in association with 5-FU/CDDP, even administered concomitantly. Despite the significant proportion of more advanced disease in the RT -CT group, LRC was similar to that obtained by RT alone. Combinations of concomitant boost RT and chemotherapy merit further investigation in prospective trials.
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Patients and methods

Patients
From January 1991 to October 1995, 87 patients with resectable or unresectable stage III-IV head and neck carcinomas were treated with concomitant boost RT, of whom 35 (40%) received combined chemoradiotherapy.
Compared with patients treated with radiotherapy al one (RT group), those receiving chemotherapy (RT -CT group) tended to have bulkier disease. The characteristics of the two groups of patients are given in Table 1 .
Radiation therapy
The treatment schedule planned to deliver a total dose of 69.9 Gy in 41 fractions over a period of 38 days. The basic course, inc1uding ail involved sites and areas of potential microscopie disease (generally the primary tumor area and both sides of the neck down to the c1avic1es), was given in daily fractions of 1.8 Gy, five times a week to a total dose of 50.4 Gy over 5.5 weeks. The boost to initial sites of macroscopic tumor involvement consisted of 13 fractions of 1.5 Gy (19.5 Gy) and was given as a second daily fraction, starting the last day of the second week of the basic treatment, in a progressively accelerated fashion ( Figure 1 ). The minimum interval between the two daily fractions was six hours. The larger volume was treated generally with two opposed laterals and one anterior field, using 6 MV photon beams in most patients. The field arrangement for the boost was individualized according to the tumor extent and location. The cervical spinal cord was blocked at a dose of 45 Gy or less, and irradiation of the posterior neck was then continued with electrons of appropriate energy. The supraclavicular lymph nodes generally received a dose of 45-50.4 Gy in 25-28 fractions. No specifie technical modifications were used in the group of patients receiving chemotherapy.
Surgery
No patient received surgery to the primary tumor. Before RT, a uni-or bilateral neck dissection was performed in 18 patients in the RT group and five in the RT -CT group (P = 0.047), and two patients in the RT group had an adenectomy.
Otherwise surgery was reserved for salvage of loco-regional failures.
Chemotherapy ln the initial patients chemotherapy was delivered sequentially prior to starting RT. Apparently satisfactory tolerance led to a gradual shift toward the administration of an increasing proportion of the chemotherapy concomitantly with RT. Thus in 10 cases chemotherapy was administered only prior to, and in 25 concomitantly with RT, either alone or with neoadjuvant and/or adjuvant chemotherapy. Except for two patients treated with weekly carboplatin, ail patients received cisplatin (CDDP), associated with 5-fluorouracil (5-FU) in 28 patients, with epirubicin + bleomycin in four patients, and administered alone in one patient. Twenty-two (63%) patients received three cycles, nine (26%) two cycles, and two (6%) one cycle. ln patients receiving at least part of their chemotherapy concomitantly with RT, chemotherapy consisted of CDDP and 5-FU in 21 patients (84%). Fourteen patients received one cycle, and seven patients two cycles, administered generally on the first and the fourth week of RT. CDDP (100 mg/m2) was given as a rapid intravenous infusion followed by
Statistical methods
The actuaria1 overall and disease-free surviva1 rates as weil as actuarial local and loco-regiona1 control rates were calculated by using the Kaplan-Meier method [19] . The Fisher's exact test, the unpaired {-test, and the logrank test were used to assess for significant differences between simple proportions, means, and survival curves respectively.
Results
AU the patients comp1eted the p1anned irradiation schedu1e except one in the RT -CT group. AU three treatment interruptions due to acute toxicity occurred in the RT -CT group (split duration 5, 17, and 35 days). The median overaU treatment time was 41 days (range 36-50 days) for the RT group and 39 days (range 37-79) for the RT -CT group. The me di an tumor dose for both groups was simi1ar (69.9 Gy, range 62.5-72.9).
Morbidity
According to the RTOG grading system [20] , aU acute reactions were grade 2 or more. The majority were grade 3 reactions, with on1y one patient in the RT group and two patients in the RT -CT group presenting with grade 4 acute toxicity. The main acute toxicity parameters for the two groups are disp1ayed in Table 2 . ln the RT -CT group, grade 3 dysphagia was more frequent with concomitant (64%) th an with neoadjuvant (45%) chemotherapy administration. According to the World Hea1th Organization (WHO) grading system [21], 12 patients (36%) in the RT -CT group presented with grade 3~hemato1ogica1 complications. Grade 3 gastrointestina1 complications were observed in four patients, and grade 3 skin reactions in one patient. Three patients presented with a vascu1ar thrombosis requiring anticoagu1ation, three with a10pecia and one with hearing impairment. Three patients in the RT group and one in the RT -CT group died during the three months fol1owing radiotherapy of causes not clearly related to tumor progression. One patient, who refused supportive care, died of malnutrition; one malnourished patient died from candida septicemia; one patient died from pneumonia as a consequence of severe laryngeal edema; and one patient died from a massive oropharyngeal hemorrhage in a setting of post -chemotherapy thrombopenia.
Seventy-three patients were evaluable for long-term complications (patients with a minimum fol1ow-up of three months and with available data). Most complications were RTOG grade 2 (52% and 42% in the RT and RT -CT groups, respectively). Grade 3-4 complications were observed in 5% and 12% in the RT and RT -CT groups, respectively (P =0.4).
Clinicalolltcome
At last fol1ow-up, 31 patients in the RT group and 17 in the RT -CT group were stil1 alive, and one patient in each group was lost to fol1ow-up (14 and Il months). ln patients having died, head and neck cancer was considered the cause of death in 14 of 20 patients in the RT group and 11 of 17 patients in the RT -CT group. The median fol1ow-up for the surviving patients was 21 months (range 2-60) and 31 months (range 4-54) for the RT and RT -CT groups, respectively.
Local and locoregional control rates were estimated for patients with a minimum follow-up of one year and without taking into account the contribution of salvage surgery. At three years actuariallocal control was 70% in the two groups and actuarial loco-regional control was 57% and 66% for the RT and RT -CT groups, respectively (P =0.66). The three-year actuarial overal1 survival was 56% and 47% (P =0.99), and the three-year disease-free survival was 53% and 60% for the RT and the RT -CT groups, respectively (P =0.8).
Discussion
Unconventional radiation fractionation schedules and the association of chemotherapy with RT represent the main innovative approaches currently under study for the treatment of unfavorable head and neck cancers. Progress in this are a has been impeded by the problem of unacceptable acute toxicity, and various strategies have been developed to assure the feasibility of these aggressive treatment programs. ln the case of accelerated RT schedules, tolerance has been variously improved by reducing the total dose (very accelerated 683 continuous course), interposing a treatment gap (accelerated split course), or reducing the volume submitted to accelerated fractionation (concomitant boost). On the other hand, for combinations of chemo-and radiotherapy, many investigators have preferred sequential or alternating schedu1es, in order to avoid the toxicity associated with the concomitant administration of the two modalities. Moreover, chemotherapy has often been limited to single agents, and RT administered using standard fractionation or using split course techniques. ln contrast, the feasibility of concomitant chemotherapy and continuous accelerated RT has not been extensively investigated.
There is increasing evidence that locoregional control can be improved through the use of various hyperfractionated and accelerated RT programs [1, 4, 6, 9, 22] . Considering the logistical convenience and the encouraging initial results of concomitant boost schedules [9] , a modified concomitant boost program was developed, in which the 13 second daily fractions were given in a progressively accelerated manner starting on day 12 of the basic treatment. This schedule design was based on the notion, as suggested by both experimental and clinical data [23, 24] , that cancer clonogen repopulation may become significant as early as two weeks after initiation of RT, and that the incremental dose required to compensate for tumor proliferation might increase progressively toward the end of treatment.
At the same time, and with the aim of increasing the efficacy ofthis accelerated RTschedule, selected patients with very advanced disease were given chemotherapy. Initially chemotherapy was given sequentially before RT, but since this mode of administration had come under serious criticism [8, 11, 25] , a decision was made to give at least part of the chemotherapy concomitantly with irradiation. The choice of 5-FU/CDDP was motivated by the reported activity of this combination in head and neck cancers [3, 12] and by the radiosensitizing properties attributed to CDDP [26, 27] .
As expected from any accelerated RT program, the rate of grade 3-4 acute reactions was high and was increased by the adjunction of chemotherapy (Table 2) . Indeed, compared with the RT group, there was greater overal1 acute toxicity and significantly more grade 3 dysphagia in the RT -CT group, and patients receiving combined treatment more frequently required hospitalization and needed significantly more nutritional support. However, it is the authors' impression that acute toxicities were equal1y manageable in the two groups, particularly when timely supportive care was provided. The most significant therapeutic disadvantage of combined treatment was the occasional disruption of RT de1ivery.
ln this retrospective analysis, locoregional control, disease-free survival, and overall survival were not significantly different between the two groups. This appears to be in contradiction to the results of sorne randomized studies comparing concomitant chemoradiotherapy with RT alone, which demonstrate significantly better loco-regional control [14] [15] [16] , and suggest a statistically significant improvement in sur vival with combined treatment [28, 29] . However, as a result of patient selection, the composition of the two groups in the present study was not at aIl similar (Table 1) . ln particular, in the RT-CT group there were fewer patients having had neck dissections and a higher percentage ofT3-T4 tumors. It is thus impossible to draw conclusions from the current study regarding the potential benefits of the combined treatment.
ln the absence of randomized comparisons the choice of RT regimen for treating unfavorable head and neck cancers will be determined by convenience, toxicity profile, and the feasibility of administration simultaneously with effective antitumor agents. Although highly accelerated continuous regimens are likely to be incompatible with such combined therapy, our initial clinical results suggest. that the concomitant boost program described in the present paper can be administered together with standard combination chemotherapy with acceptable toxicity. The locoregional control obtained in the present series of patients with stage III-IV disease is encouraging. A confirmation of these results in prospective studies appears justified.
